"Malawi to Conduct Anti-HIV Vaccine Trials"
Malawi will begin in May clinical trials of an experimental HIV vaccine, known as MRKAd5-HIV-1 gag, that targets HIV-1. The first phase of the clinical trial, which will involve 435 people worldwide, including as many as 44 Malawians, will determine if the vaccine is safe for human use as well as effective in producing an immune response. Participants must be HIV-negative, at low risk of contracting the virus, able to use contraceptives for the first 12 months of the study, and committed to a follow-up after five years, according to Jane Mallewa, study coordinator at Johns Hopkins Project in Blantyre. The research is being funded by the U.S. National Institutes of Health via the HIV Vaccine Trial Network. (Web Link)
Elizabeth Bell, MPH
STOP Activity Unit
Polio Eradication Branch
Global Immunization Division
Centers for Disease Control and Prevention